Rothschild & Co Redburn downgraded Danaher (DHR) to Neutral from Buy with a price target of $220, down from $245. The shares trade at a premium valuation but the company’s 2025 and 2026 growth outlook remains well below historical levels, the analyst tells investors in a research note. The firm believes Danaher’s valuation reflects a return to historical growth trends in its life science markets, but Rothschild sees limited visibility on the pace of recovery in China and the sustainability of diagnostics growth. As such, it sees limited upside to Danaher’s estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target lowered to $220 from $230 at BofA
- Danaher Updates By-laws and Launches Share Buyback
- A10 Networks CFO Brian Becker to step down, Michelle Caron to succeed
- Danaher price target lowered to $241 from $250 at RBC Capital
- Third Point boosts position in Nvidia, takes new stakes in Mr Cooper, Meta